Skip to main content

Comprehensive bronchoalveolar lavage characterization in COVID-19 associated acute respiratory distress syndrome patients: a prospective cohort study


COVID-19-related acute respiratory distress syndrome (CARDS) is associated with high mortality rates. We still have limited knowledge of the complex alterations developing in the lung microenvironment. The goal of the present study was to comprehensively analyze the cellular components, inflammatory signature, and respiratory pathogens in bronchoalveolar lavage (BAL) of CARDS patients (16) in comparison to those of other invasively mechanically ventilated patients (24). In CARDS patients, BAL analysis revealed: SARS-CoV-2 infection frequently associated with other respiratory pathogens, significantly higher neutrophil granulocyte percentage, remarkably low interferon-gamma expression, and high levels of interleukins (IL)-1β and IL-9. The most important predictive variables for worse outcomes were age, IL-18 expression, and BAL neutrophilia. To the best of our knowledge, this is the first study that was able to identify, through a comprehensive analysis of BAL, several aspects relevant to the complex pathophysiology of CARDS.


The vast spectrum of clinical manifestations of SARS-CoV-2 infection ranges from asymptomatic or paucisymptomatic forms to severe pneumonia with acute respiratory distress syndrome (ARDS) requiring often admission to an intensive care unit (ICU) [1] with in-ICU mortality ranging in Europe from 28 to 42% [2]. COVID-19-associated ARDS (CARDS) has often been associated with rapid virus replication, inflammatory cell infiltration, and elevated cytokines resulting in multiorgan failure, mainly pulmonary [3, 4]. We still have limited knowledge of the complex alterations developing in the lung microenvironment of patients with CARDS. Most studies have used blood, plasma, and/or serum [5,6,7], while only few were performed in BAL samples reporting heterogeneous results [8,9,10,11,12]. A comprehensive comparative study with appropriate controls allowing for inflammatory and infection profiling of BAL has not yet been done.

Accordingly, the goal of the present study was to compare cellular components, inflammatory signatures, and the main pathogens in BALs collected from CARDS patients and two different control groups of invasively mechanically ventilated (IMV) patients (healthy and frail patients) drawn from the same ICU. An additional exploratory goal was to identify the most important factors that discriminate worse outcomes.

Materials and methods

We performed a prospective single-center cohort study enrolling 16 CARDS cases admitted to the ICU of Padova University Hospital between April 30th and August 31st, 2021, following specific inclusion and exclusion criteria (Fig. 1).

Two different control groups were used: frail controls: “immunocompromised” (IC) controls including lung transplant (LT) recipients (n = 12); and “healthy” controls including lung donors (n = 12). SARS-CoV-2 RT-PCR was carried out and cases with sufficient viral load (< 27 Ct) were sequenced using a Genetic Analyzer (Applied Biosytems, Foster City, CA, USA). All patients in the control groups were negative for SARS-CoV-2 and recruited in the same time interval as that of CARDS. BAL from healthy controls was negative for any kind of infection (so called “sterile” BAL) and collected within three days after ICU admission. BALs from IC controls and from all CARDS cases were collected within two weeks after ICU admission. The study was approved by the Institutional Ethics Committee of Padova (number: 5245/AO/21; April 15th, 2021) and was conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained according to national regulations. All investigations were performed on de-identified data. For each CARDS case and each IC control, demographic characteristics, clinical and laboratory data, medical treatments, ICU/hospital length of stay, ICU/hospital mortality, and radiological data were collected in electronic medical records (Table 1, original datasets at Details on BAL processing for microbiological, cytological and molecular analyses of inflammatory mediators, as well as the statistical analyses performed, can be found in the Additional file 1.

Fig. 1
figure 1

CONSORT diagram describing the study population and design

Table 1 Clinical characteristic of study population at enrollment


While gender, age, and BMI are not different in the three groups, CARDS cases show a slightly higher BMI and hypertension prevalence (Table 1). Real-time PCR for SARS-CoV-2 was positive in all BALs of CARDS cases with a mean of 27.65 CT (range from 16 to 35). SARS-CoV-2 sequence analysis resulted in variant Alpha. All BALs from controls were negative. At least one bacterial isolate was detected in 5 (31%) CARDS cases and in 5 (42%) IC controls. Fungi were found in 5 (31%) CARDS patients and in none of the IC control group. As expected, no cultivable bacteria or fungi were detected in BALs from healthy controls (Table 2). Molecular analysis of viruses and no cultivable bacteria revealed viral infection in 5 BALs (31%) from CARDS cases and in 5 (42%) from the IC controls (Table 2). None of the healthy controls were positive for the microorganisms investigated by molecular analyses (Table 2). Cytological analysis of BALs from CARDS cases were frequently rich in mucus and showed high cellularity, mainly neutrophils (15/16,94%). Neutrophilic granulocyte percentage was significantly increased in BAL samples from CARDS cases (median %, IQR: 55, 40–90 vs. 0, 0-2.25; p < 0.001) while lymphocytic and macrophagic values were significantly lower than in the IC control group (median %, IQR: 0, 0–0 vs. 5, 4.5–10 for lymphocytes, 40, 10–50 vs. 90, 90-93.5 for macrophages). Reactive pneumocytes, fibrin and blood were present in almost all CARDS cases (87.5%, 100% and 93.8%, respectively). Molecular expression analysis of inflammatory mediators showed significant differences in the expression of IL-9, IL-1β, IFN-γ, IFN-α7 and IFN-α8 (Table 3; Fig. 2). In particular, IFN-γ was less expressed in CARDS patients than IC controls (equal to healthy controls) (p = 0.04) while IL-9 and IL-1β were significantly more expressed in CARDS cases than in IC controls and healthy controls (p = 0.01 and p = 0.005). Some explanatory cases are presented in the Additional file 2 and 3. Statistical analysis showed that BAL neutrophil granulocyte percentage of CARDS cases was higher independently from the presence of concomitant infection, hospital LOS and ICU LOS. Similarly, no difference in cytokine expression was detected when comparing CARDS patients with or without coinfections. All cellular components, cytokine profile, and infectious agents of CARDS cases seem not to be associated with clinical data such as age, sex, BMI, ICU, and hospital LOS (using the Spearman non-parametric correlation test). The Boruta algorithm using all cytokine quantification, blood tests, bacterial, viral, and fungal infections, age, gender, and BMI as predictors showed that the most important variables determining the outcome were: age for mortality, no variable for ICU stay, IL-18 for hospital LOS, and BAL neutrophil granulocytes percent in case of ECMO.

Table 2 Microbiological findings of the study population
Table 3 Inflammatory mediator profiles
Fig. 2
figure 2

Comparison of the median ΔCt values of IL-9 (a), IL-1β (b), IFN-γ (c), and IL-6 (d) in CARDS patients, IC and healthy controls. IFN-γ was less expressed in CARDS patients than IC controls (equally to healthy controls) (p = 0.04) while IL-9 and IL-1β were significantly more expressed in CARDS cases than in IC controls and healthy controls (p = 0.01 and p = 0.005). No statistical significance was achieved for IL-6


To the best of our knowledge, this is the first study identifying relevant aspects of CARDS patients through a comprehensive analysis of different BAL aspects (cellular components, inflammatory signature, and infections). Specifically concerning microbial investigation, interestingly we detected the SARS-CoV-2 viral genome in all BALs from CARDS cases including those with a longer history of disease. Several studies have found prolonged viral shedding in BAL from critically ill patients compared to upper-respiratory tract specimens [13]. This may be related to the lack of neutralizing antibodies, which favor a greater number of “free” virions unbound by immune complexes thus contributing to prolonged infectivity [13]. Although there is still conflicting data about viral load and outcome, the most recent evidence on large case series indicates higher mortality in patients with higher viral load [13] Data from a very recent study investigating the microbiome and host immune profile indicate that the abundance of SARS-CoV-2 in the lower airways associated with a low host immunological response is a predictive sign of mortality [13]. Many bacteria and rare viruses were detected in our CARDS cases, some of them like those of the IC controls, such as Klebsiella pneumoniae, Staphylococcus aureus, and viral genomes (i.e., EBV and HSV1). Fungal infections were detected only in CARDS cases, which were responsible for COVID-associated pulmonary aspergillosis (CAPA). The incidence of CAPA in critically ill COVID-19 patients is estimated to be between 26.3 and 33% [14, 15]. An interesting recent study by Viciani et al. on the lung microbiome supports the evidence that lung fungal dysbiosis is more severe in CARDS [16]. Analysis of the cellular components and overall cytokine expression in our study revealed intriguing findings. BALs showed high cellularity with a neutrophilic pattern in many cases (in 55% of cases). It is noteworthy that the neutrophilic pattern was not influenced by bacterial and fungal infections. In line with our observations indicating increased BAL neutrophils as a worse predictive factor for ECMO, an increased number of hyperactivated neutrophils was recently found in BAL of critical COVID-19 patients that required IMV and/or ECMO [12]. Excessive neutrophil extracellular trap generation and higher frequencies of immature neutrophils with an immunosuppressive phenotype have been proposed as novel therapeutic targets in critical COVID-19 patients [17]. Comparative analysis of inflammatory cytokine levels showed a significant IFN-γ downregulation in CARDS cases, similarly to healthy controls. While this was an expected finding in the healthy group, given that the patients are infection-free, this should not have been the case in the CARDS cases where either high SARS-CoV-2 viral load or other superinfections were found. Considering the immune role played by IFN-γ, we expected IFN-γ to be at least present if not highly expressed. Few studies have evaluated IFN-γ expression in COVID-19 patients, and they presented conflicting results mainly in relation to the source of investigation (BAL vs. blood vs. swab) and the time of disease (early vs. late) [18,19,20]. Preservation of the IFN-γ response in the IC controls further supports the evidence of impairment of antiviral defenses associated with SARS-CoV-2 infection more than an impairment related to iatrogenic immunosuppression (steroid therapy). Investigations on the IFN family, particularly IFN-γ in patients with COVID-19 and particularly those with CARDS need an urgent and in-depth analysis due to its possible use as a theragnostic biomarker. Finally, our results show significantly overexpressed IL-1β and IL-9 in CARDS cases. A previous study that investigated several cytokines in BAL supporting our data and showing that the expression of different cytokines, including IL-1β, was significantly higher in severe and critically ill COVID-19 patients (6 patients) [7]. IL-9 was undoubtedly the most characterizing inflammatory cytokine in our study population, because it was over-expressed only in the CARDS cases. Feng et al. [21] evaluated the mechanistic role played by IL-9 in deep venous thrombosis and provided data that supports a pro-thrombosis role played by IL-9. Considering that one of the major complications of CARDS are thromboembolic injuries in the pulmonary vascular bed [22,23,24], this finding may provide a basis for IL-9 suppressive intervention in COVID-19 disease, especially in critically ill patients. In addition to high BAL neutrophil percentage as a predictive marker for ECMO, age was found as another important predictive variable for mortality, as consistently reported in the literature [2, 25,26,27]. The present research is limited by its relatively small sample size: this reflects the rapid decline in the incidence of SARS-CoV-2 infections during the study period compared to the major pandemic waves. However, one of the strengths of this study was the inclusion of two control groups (an “immunocompromised” group and a “healthy” group) recruited during the same interval time and in the same ICU, and the use of robust statistical techniques, the results of which are useful to better understand the pathophysiology of complex host/microenvironment interaction and to mitigate some influencing factors (e.g., immunosuppressive therapy, IMV). At the same time, we are aware that a robust analytical method can only mitigate the small number of cases, thus further studies are needed to assess the generalization of our findings. In summary, this prospective comprehensive comparative BAL investigation of CARDS showed relevant features: the persistence of SARS-CoV-2 associated with superinfections, the marked BAL neutrophilia, and a specific cytokine set. We strongly believe that our findings may contribute to a better understanding of the complex pathophysiology of CARDS. These findings need additional research studies to explore mechanistic pathways.

Availability of data and materials

The datasets supporting the conclusions of this article are available in the repository



Acute respiratory distress syndrome


Bronchoalveolar lavage


Body mass index


COVID-associated pulmonary aspergillosis


COVID-19-related acute respiratory distress syndrome




Epstein-Barr virus


Extracorporeal membrane oxygenation


Herpes virus simplex




Intensive care unit






Invasive mechanically ventilated


Interquartile range


Length of stay


Lung transplant


Real Time polymerase chain reaction


World Health Organization


  1. Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case characteristics, resource use, and outcomes of 10,021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;8:853–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Boscolo A, Sella N, Lorenzoni G, Pettenuzzo T, Pasin L, Pretto C, et al. Static compliance and driving pressure are associated with ICU mortality in intubated COVID-19 ARDS. Crit Care. 2021;25:263.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34:327–31.

    CAS  PubMed  Google Scholar 

  4. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Zaid Y, Doré É, Dubuc I, Archambault AS, Flamand O, Laviolette M, et al. Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19. J Allergy Clin Immunol. 2021;148:368-80e3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Famous KR, Delucchi K, Ware LB, Kangelaris KN, Liu KD, Thompson BT, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017;195:331–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26:842–4.

    Article  CAS  PubMed  Google Scholar 

  8. Saris A, Reijnders TDY, Nossent EJ, Schuurman AR, Verhoeff J, Asten SV, et al. Distinct cellular immune profiles in the airways and blood of critically ill patients with COVID-19. Thorac Surg Clin. 2021;76:1010–9.

    Google Scholar 

  9. Patrucco F, Albera C, Bellocchia M, Foci V, Gavelli F, Castello LM, et al. SARS-CoV-2 detection on Bronchoalveolar Lavage: an italian multicenter experience. Respiration. 2020;99:970–8.

    Article  CAS  PubMed  Google Scholar 

  10. Dentone C, Vena A, Loconte M, Grillo F, Brunetti I, Barisione E, et al. Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy. BMC Infect Dis. 2021;21:353.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Baron A, Hachem M, Van Tran J, Botterel F, Fourati S, Carteaux G, et al. Bronchoalveolar Lavage in patients with COVID-19 with invasive mechanical ventilation for acute respiratory distress syndrome. Ann Am Thorac Soc. 2021;18:723–6.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Cambier S, Metzemaekers M, de Carvalho AC, Nooyens A, Jacobs C, Vanderbeke L, et al. Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID-19 from influenza. JCI Insight. 2022;7:e155055.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Sulaiman I, Chung M, Angel L, Tsay JJ, Wu BG, Yeung ST, et al. Microbial signatures in the lower airways of mechanically ventilated COVID-19 patients associated with poor clinical outcome. Nat Microbiol. 2021;6:1245–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21:e149-62.

    Article  CAS  PubMed  Google Scholar 

  15. Alanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020;8:e48-9.

    Article  CAS  PubMed  Google Scholar 

  16. Viciani E, Gaibani P, Castagnetti A, Liberatore A, Bartoletti M, Viale P, et al. Critically ill patients with COVID-19 show lung fungal dysbiosis with reduced microbial diversity in patients colonized with Candida spp. Int J Infect Dis. 2022;117:233–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Hazeldine J, Lord JM. Neutrophils and COVID-19: active participants and rational therapeutic targets. Front Immunol. 2021;12:680134.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020;584:463–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Sposito B, Broggi A, Pandolfi L, Crotta S, Clementi N, Ferrarese R, et al. The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell. 2021;184:4953-68e16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ward JD, Cornaby C, Schmitz JL. Indeterminate QuantiFERON gold plus results reveal deficient Interferon Gamma responses in severely ill COVID-19 patients. J Clin Microbiol. 2021;59:e0081121.

    Article  PubMed  Google Scholar 

  21. Feng Y, Yu M, Zhu F, Zhang S, Ding P, Wang M. IL-9 promotes the development of deep venous thrombosis by facilitating platelet function. Thromb Haemost. 2018;118:1885–94.

    Article  PubMed  Google Scholar 

  22. Calabrese F, Pezzuto F, Fortarezza F, Boscolo A, Lunardi F, Giraudo C, et al. Machine learning-based analysis of alveolar and vascular injury in SARS-CoV-2 acute respiratory failure. J Pathol. 2021;254:173–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Fortarezza F, Pezzuto F, Hofman P, Kern I, Panizo A, von der Thüsen J, et al. COVID-19 pulmonary pathology: the experience of European pulmonary pathologists throughout the first two waves of the pandemic. Diagnostics (Basel). 2022;12:95.

    Article  CAS  PubMed  Google Scholar 

  24. Zarrilli G, Angerilli V, Businello G, Sbaraglia M, Traverso G, Fortarezza F, et al. The immunopathological and histological Landscape of COVID-19-Mediated Lung Injury. Int J Mol Sci. 2021;22:974.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med. 2020;48:e440-69.

    Article  PubMed  Google Scholar 

  27. Vaschetto R, Barone-Adesi F, Racca F, Pissaia C, Maestrone C, Colombo D, et al. Outcomes of COVID-19 patients treated with continuous positive airway pressure outside the intensive care unit. ERJ Open Res. 2021;7:00541–2020.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


The authors would like to thank Dr. Veronica Tauro for the contribution in performing molecular analyses and Dr. Luisa Muraro, Arianna Peralta, Eugenio Serra for helping in the collection of clinical data.


The research was partially funded by the GILEAD Fellowship Program 2021 and by fellowships from the University of Padova (Intesa San Paolo Vita bank) for young pathologists (FF, EGO), without any role in the design of the study, analysis and interpretation of the data (2020A08).

Author information

Authors and Affiliations



FC, FR, PN conceptualized the study; FC, CDV, AMC, DG, FR, PN supervised the analyses; FC, FL, GEO, AB wrote the manuscript; FC, LV, AMC, FR, PN reviewed the manuscript; FL, EB, FP, AK, GEO, FF, AB, MS: performed the analyses; DG, LV performed the statistical analyses. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Fiorella Calabrese.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Institutional Ethics Committee of Padova (title of the study: “Multidisciplinary approach for the diagnosis of pulmonary aspergillosis in high-risk patients recovered in ICU: clinical-pathological, microbiological and molecular correlations”, center approval reference number: 5245/AO/21; April 15th, 2021) and was conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained according to national regulations. All investigations were performed on de-identified data.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

Additional details concerning Materials and Methods.

Additional file 2.

Explanatory case 1, showing a high number of neutrophils (a, hematoxylin and eosin staining, 40x original magnification) in BAL of a CARD patient without superinfection. IFN-γ was not detected while IL1β and IL-9 were found by molecular analyses (b, c and d, respectively).

Additional file 3.

Explanatory case 2, showing a high number of neutrophils (a, hematoxylin and eosin staining, 40x original magnification) in BAL of a CARDS patient with a concurrent Aspergillus infection and numerous hyphae well seen at high magnification with special stain (b, PAS staining, 40x original magnification). IFN-γ was not detected by molecular analyses (c).

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Calabrese, F., Lunardi, F., Baldasso, E. et al. Comprehensive bronchoalveolar lavage characterization in COVID-19 associated acute respiratory distress syndrome patients: a prospective cohort study. Respir Res 24, 152 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • ARDS
  • Bronchoalveolar lavage
  • COVID-19
  • Cytokine profile
  • Microbiology